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Abstract 
 
The stable ascorbic acid derivative 2-O-α-D-glucopyranosyl-L-ascorbic acid 
(AA-2G) was used to investigate the role of ascorbic acid (AA) in B cell 
differentiation in vitro. AA-2G is stable in a solution unlike AA but is hydrolyzed 
by cellular α-glucosidase to release AA. Mouse spleen B cells were primed for 2 
days with an anti-μ antibody in the presence of interleukin (IL)-4 and IL-5 and 
then washed and recultured with AA-2G in the presence of IL-4 and IL-5. AA-2G, 
but not AA, dose-dependently increased IgM production, the greatest 
enhancement being 150% at concentrations of more than 0.5 mM. In the absence 
of IL-4 and IL-5, primed B cells produced a negligible amount of IgM, and 
AA-2G had no effect. AA-2G-induced IgM production in the presence of IL-4 
and IL-5 was inhibited by the α-glucosidase inhibitor castanospermine. 
Intracellular AA content, depleted during the priming period, increased by adding 
AA-2G at the start of reculture. Treatment of B cells with AA-2G resulted in an 
increase in the number of IgM-secreting cells, CD138-positive cells and 
CD45R/B220-negative cells. The number of viable cells in untreated cultures 
decreased gradually, but the decrease was significantly attenuated by AA-2G, 
resulting in about 70% more viable cells in AA-2G-treated cultures. AA-2G 
caused a slight but reproducible enhancement of DNA synthesis and a slight 
decrease in the number of cells with a sub-G1 DNA content. These results 
demonstrated that AA released from AA-2G enhanced cytokine-dependent IgM 
production in anti-μ-primed B cells and suggest that its effect is caused through 
promoting the differentiation of B cells to plasma cells and attenuating the gradual 
decrease in the number of viable cells. 
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1. Introduction 
 
Cells of the immune system produce a large amount of reactive oxygen 
species as part of their normal functions such as chemotactic locomotion and 
phagocytosis. Whereas reactive oxygen species play an essential role in the 
intracellular killing of bacteria and other invading organisms, immune cells are 
sensitive to reactive oxygen species because of the high percentage of 
polyunsaturated fatty acids in plasma membranes of those cells [1]. A high 
cellular concentration of the antioxidant ascorbic acid (AA) in immune cells 
might contribute to the prevention of cellular damage mediated by reactive 
oxygen species and might have a modulatory role in the process of immune 
response [2]. In fact, several studies have shown in vitro and in vivo 
immunostimulatory effects of AA. Supplementation with AA in healthy subjects 
enhanced neutrophil chemotaxis and T lymphocyte proliferation [3-5]. 
Administration of AA in patients exposed to toxic chemicals enhanced natural 
killer (NK) cell activity and improved lymphocyte blastogenic responses to T and 
B cell mitogens [5-8]. In vitro treatment with AA was shown to stimulate 
phagocytosis of peritoneal macrophages and NK cell activity [9]. However, there 
have been few studies on the effects of AA on antibody production, and it is 
unknown whether or not B cell differentiation is promoted by AA. In vitro 
differentiation of B cells into antibody-producing plasma cells requires a culture 
period of several days, during which time exogenously added AA in a medium is 
oxidatively degraded and intracellular AA is depleted. Thus, the instability of AA 
in an aqueous solution is a major problem to use it in experiments of in vitro 
antibody production.  
We have synthesized an AA derivative, 2-O-α-D-glucopyranosyl-L-ascorbic 
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acid (AA-2G), that is stable in a solution unlike AA but is hydrolyzed by cellular 
α-glucosidase to release AA [10-13]. In order to determine the role of AA in B 
cell differentiation, we investigated in this study whether AA-2G augments 
cytokine-dependent antibody production in in vitro anti-μ-primed B cells enriched 
from murine splenocytes. The results showed that AA released from AA-2G 
potently enhanced production of IgM by anti-μ-primed B cells through promoting 
the differentiation of B cells to plasma cells and attenuating a decrease in the 
number of viable cells. 
 
2. Materials and methods 
 
2.1. Reagents   
 
AA-2G was donated from Hayashibara Biochemical Laboratories, Inc. 
(Okayama, Japan). AA-2G was dissolved in phosphate-buffered saline, 
neutralized with NaOH, adjusted to 100 mM, and filtered before use. The F(ab’)2 
fragment of goat anti-mouse IgM antibody (Ab) (μ chain-specific) was obtained 
from Jackson Immunoresearch Laboratories (West Grove, PA, USA). 
Recombinant mouse interleukin (IL)-4 and IL-5 were purchased from R&D 
Systems (Minneapolis, MN, USA). L-Ascorbic acid 2-phosphate (AA-2P) 
sesquimagnesium salt, L-ascorbic acid 2-sulfate (AA-2S) dipotassium salt, and 
propidium iodide (PI) were obtained from Sigma Chemical Co. (St. Louis, MO, 
USA). Castanospermine and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic 
acid (Trolox) were pruchased from Wako Pure Chemical Industries (Osaka, 
Japan) and Calbiochem (La Jolla, CA, USA), respectively. Purified mouse IgM, 
goat anti-mouse IgM Ab, and horseradish peroxidase (HRP)-conjugated goat 
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anti-mouse IgM Ab were obtained from Zymed Laboratories Inc (San Francisco, 
CA, USA), Organon Teknika Corporation (Durham, NC, USA), and Kirkegaad & 
Perry Laboratories (Gaithersburg, MD, USA), respectively. Fluorescein 
isothiocyanate (FITC)-conjugated rat anti-mouse CD45R/B220, phycoerythrin 
(PE)-conjugated rat anti-mouse CD138 (syndecan-1), and anti-mouse 
CD16/CD32 monoclonal Abs (mAbs) were purchased from BD Biosciences 
Pharmingen (San Jose, CA, USA). [6-3H]Thymidine was obtained from GE 
Healthcare Bio-Sciences Corp. (Little Chalfont, UK).  
 
2.2. Mice 
 
Female BALB/c mice, purchased from Charles River Japan (Yokohama, 
Japan), were maintained under specific pathogen-free conditions in the animal 
facility of Okayama University and used between 8 and 12 weeks of age. 
Experimental procedures involving mice were approved by the Animal Research 
Control Committee of Okayama University. 
 
2.3. Preparation of enriched B cells   
 
Murine spleen resting conventional (CD5−) B cells were enriched by 
negative selection using a mouse B lymphocyte enrichment set (BD Biosciences 
Pharmingen) as decribed previously [14]. Briefly, murine spleen cells depleted of 
erythrocytes by lysis of erythrocytes with ammonium chloride were suspended in 
Dulbecco’s modified Eagle’s medium supplemented with 4 mM L-glutamine, 100 
U/mL penicillin and 100 μg/mL streptomycin and incubated on plastic dishes for 
90 min at 37 °C. The nonadherent cells were then collected, suspended in the 
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same medium, and incubated on ice for 60 min with biotin-conjugated anti-mouse 
CD4, CD43 and TER-119/erythroid cell mAbs. The cells bearing the biotinylated 
antibodies were bound to BD IMag streptavidin particles, and negative selection 
was then performed on a BD IMagnet according to the manufacturer’s protocol to 
enrich unlabeled B cells. The purity of recovered viable B cells ranged between 
97% and 98% when the cells were stained with FITC-conjugated anti-mouse 
CD45R/B220 mAb and PI after preincubation of the cells with anti-mouse 
CD16/CD32 mAb to block Fc-mediated binding of Ab to the Fcγ receptor of cells 
and analyzed by a flow cytometer (Epics XL, Beckman Coulter, Miami, FL, 
USA). More than 95% cells in the enriched B cell preparations were small, 
resting B cells as judged by the cell size (forward scatter) in flow cytometry. 
 
2.4. Antibody response of enriched B cells stimulated with anti-μ, IL-4 and IL-5   
 
A two-step culture system described previously was used [15,16]. Enriched B 
cells were suspended in basal culture medium (RPMI 1640 medium, 
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 
100 U/mL of penicillin G and 100 μg/mL of streptomycin) and primed with anti-μ 
(10 μg/mL) in the presence of IL-4 (5.6 ng/mL) and IL-5 (6 ng/mL) for 2 days in 
flat-bottom 96-well plates (1.2 × 106 cells/200 μL/well) at 37 °C in an atmosphere 
containing 5% CO2. The cells were washed twice with the basal culture medium 
to remove anti-μ and then recultured with or without AA or AA-2G in the 
presence of IL-4 (5.6 ng/mL) and IL-5 (6 ng/mL) for the indicated days in 
triplicate in round-bottom 96-well plates at a density of 1 × 105 cells/200 μL/well. 
The culture supernatant was then collected and was frozen at −30 °C for an IgM 
ELISA. The IgM levels were assayed by a sandwich ELISA essentially as 
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described previously [17] . 
 
2.5. Enzyme-linked immunospot (ELISPOT) assay for detection of polyclonal 
IgM-secreting cells   
 
The ELISPOT assay was performed as described previously [18] . Briefly, 
each well of 96-well microtiter plates was coated with 50 μL of goat anti-mouse 
IgM Ab (10 μg/mL) by being incubated overnight at 4 °C and then washed three 
times with PBS containing 0.05% Tween-20. The plates were blocked with 200 
μL of 1% BSA in PBS for 2 h at room temperature and washed. To those plates, 
enriched B cells, which had been incubated with or without AA-2G for 4.5 days 
in the reculture period and washed with and suspended in the basal culture 
medium, were added (1 × 103 viable cells/200 μL/well) in triplicate and incubated 
for 12 h at 37 °C. After being washed three times, the plates was incubated with 
50 μL of HRP-conjugated goat anti-mouse IgM Ab (0.2 μg/mL) for 1 h at room 
temperature. After washing, 100 μL of substrate solution consisting of 50 mM 
sodium phosphate buffer (pH 7.0), 1% agarose, 2 mg/mL of diaminobenzidine, 
0.0018% H2O2, 0.0018% NiCl2, and 0.0018% CoCl2 was added. The plates were 
then incubated overnight at 37 °C in the dark, and the number of spot-forming 
cells was counted under a stereomicroscope. The data are expressed as number of 
spot-forming cells per culture. 
 
2.6. Flow cytometric analysis of cell surface antigen expression   
 
Enriched B cells, which had been incubated with or without AA-2G for 4 days 
in the reculture period, were pooled and washed with and suspended in PBS 
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containing 0.5% BSA and 0.1% sodium azide (~ 1 × 106 cells/100 μL). The cells 
were then incubated with anti-mouse CD16/CD32 mAb (10 μg/mL) for 5 min on 
ice and stained with FITC-conjugated anti-mouse CD45R/B220 mAb (10 μg/mL) 
or PE-conjugated rat anti-mouse CD138 mAb (4 μg/mL) for 30 min on ice. After 
being washed with and suspended in PBS containing 0.5% BSA and 0.1% sodium 
azide, the cells were stained with PI (2 μg/mL), and expression of CD45R/B220 
and CD138 on viable cells was analyzed by a flow cytometer (Epics XL, 
Beckman Coulter).  
 
2.7. Determination of apoptotic cells   
 
Apoptotic cells were determined as described previously [19]. Briefly, 
enriched B cells (~ 2 × 106 total cells), which had been incubated with or without 
AA-2G for 2 and 4 days in the reculture period, were pooled, washed twice with 
cold PBS, and fixed with 200 μL of 70% ethanol for 4 h at 4°C. After being 
washed with PBS, the cells were incubated with ribonuclease A (0.1 mg/mL) in 
100 μL of PBS for 30 min at 37 °C. The cells were then washed with and 
suspended in 1 mL of PBS and incubated with PI (50 μg/mL) for 30 min at room 
temperature in the dark. The DNA contents of cells were analyzed by a flow 
cytometer (Epics XL, Beckman Coulter). The cells with a sub-G1 DNA content 
were regarded as apoptotic cells. 
 
2.8. Determination of DNA synthesis   
 
Enriched B cells, which had been incubated with or without AA-2G for 1−4 
days in the reculture period, were pulse-labeled with [3H]thymidine (0.5 μCi/well, 
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2.5 Ci/mmol) for the last 4 h and harvested on glass fiber filters as described 
previously [14]. The amount of [3H]thymidine incorporated was measured in a 
liquid scintillation counter. The activity of DNA synthesis was calculated as 
incorporated [3H]thymidine per 105 viable cells. The number of viable cells in 
parallel cultures was determined by a trypan blue dye-exclusion test.  
 
2.9. Determination of intracellular AA contents   
 
Enriched B cells (0.5−4 × 106 viable cells), which had just been prepared or 
had been incubated for 2 days in the priming period and for 2 and 4 days with or 
without AA-2G in the reculture period, were pooled, washed three times with cold 
PBS, and stored at −80°C until analyses. The cells were then suspended in 100 μL 
of cold 1% metaphosphoric acid and sonicated. The cell homogenates were 
centrifuged, and the resulting supernatant was subjected to HPLC analysis for 
estimating AA. The separation of AA was achieved by isocratic elution from an 
Inertsil ODS-3 column (4.6 i.d. × 250 mm, 5 μm; GL Sciences, Tokyo, Japan) 
with a guard column of Inertsil ODS-3 (4.6 i.d. × 10 mm, 5 μm; GL Sciences) 
kept at 40°C with 0.1 M potassium phosphate-phosphoric acid buffer (pH 2.1) 
containing 10 mg/L of EDTA at a flow rate of 0.7 mL/min as described 
previously [20]. The absorbance at 240 nm was monitored, and the AA content 
was determined from the peak area of the sample with reference to the calibration 
by authentic AA. The intracellular AA contents are expressed as ng per 106 viable 
cells. 
   
2.10. Data Analysis   
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Results are expressed as means and S.D. of three or four independent 
experiments. Data in two groups were analyzed by Student’s t-test. Multiple 
comparison of the data was done by Dunnett’s t-test, Bonferroni’s test or 
Dunnett’s T3-test. P values less than 5% were regarded as significant. 
 
3. Results 
 
3.1. Enhancement by AA-2G of IgM production by B cells stimulated with anti-μ 
      
Murine spleen B cells were primed with anti-μ in the presence of IL-4 and 
IL-5 and then washed and recultured with or without varying doses (0.063-1 mM) 
of AA in the presence of IL-4 and IL-5 for 5 days. IgM production was not 
increased by AA (0.063-0.25 mM), and it was rather decreased by high 
concentrations of AA (0.5 and 1 mM) (Fig. 1A). In contrast, AA-2G 
dose-dependently increased IgM production, the greatest enhancement being 
150% at concentrations of more than 0.5 mM (Fig. 1A). IgM production was not 
further potentiated when AA-2G was included in both the priming period and the 
reculture period (data not shown). Anti-μ-primed B cells produced only a trace 
amount of IgM in the absence of IL-4 and IL-5 as previously reported by Phillips 
and Klaus [15] and Weber et al. [16]. The stimulatory effect of AA-2G was not 
observed in the absence of IL-4 and IL-5 (Fig. 1B). Figure 1C shows a time 
course for AA-2G-induced increase in IgM production. B cells cultured without 
AA-2G produced a minimal amount of IgM during the initial 2 days of secondary 
culture but produced a significant amount of IgM thereafter. The enhancing effect 
of AA-2G was not observed before day 4 of secondary culture.  
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3.2. Enhancing effect of AA-2G mediated by released AA  
      
AA-2G is hydrolyzed by cellular α-glucosidase to release AA [11]. To 
determine whether the enhancing effect of AA-2G on IgM production is mediated 
by AA, we employed castanospermine, an alkaloidal inhibitor of α-glucosidase 
[21]. Castanospermine was added to anti-μ-stimulated B cells in the second 
culture with AA-2G, and the cultures were incubated for 5 days. AA-2G-induced 
IgM production was almost completely inhibited to the level of cultures without 
AA-2G by 2 μM castanospermine, which had no effect on IgM production in 
cultures without AA-2G (Fig. 2A). Changes in AA contents in cells cultured with 
or without AA-2G were then determined. As shown in Fig. 2B, intracellular AA 
contents were depleted to undetectable levels at the end of the first culture. 
Addition of 0.5 mM AA-2G to the cells at the start of the second culture caused a 
marked increase in intracellular AA contents to more than the initial levels.  
  
3.3. Effects of other stable AA derivatives and antioxidants on IgM production by 
B cells  
 
AA-2P and AA-2S are also known as stable AA derivatives. AA-2P has been 
shown to increase collagen synthesis in human fibroblasts, and it has an 
antiscorbutic activity in guinea pigs and monkeys, whereas AA-2S does not have 
either activity [22-24]. AA-2P but not AA-2S is appreciably cleaved by lysates of 
human dermal fibroblasts to release AA [22]. These results suggest that AA-2P 
but not AA-2S is hydrolyzed by cells in culture and in vivo. Effects of both 
derivatives on IgM production by B cells stimulated with anti-μ, IL-4 and IL-5 
were compared with the effect of AA-2G. As shown in Fig. 2C, AA-2P, but not 
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AA-2S, increased IgM production as markedly as did AA-2G.  
Effects of some antioxidants on IgM production by anti-μ-primed B cells were 
shown in Fig. 2D. Trolox, a cell-permeable derivative of vitamin E, glutathione 
and uric acid did not enhance IgM production.  
 
3.4. Enhancement by AA-2G of differentiation of anti-μ-stimulated B cells 
      
In order to confirm enhanced differentiation of B cells treated with AA-2G, 
the number of antibody-secreting cells in cultures treated with or without AA-2G 
for 4.5 days in the reculture period was determined by the ELISPOT assay, and 
the results are expressed as number of spots per reculture. Treatment with 0.5 mM 
AA-2G resulted in 160% increase in the number of IgM-secreting cells (Fig. 3A). 
It is known that differentiation of naive B cells to plasma cells is accompanied by 
an increase in CD138 expression and by a decrease in CD45R/B220 expression 
[25,26]. B cells treated with or without AA-2G for 4 days in the second culture 
were subjected to analyses of expression of both cell-surface antigens by a flow 
cytometer. AA-2G significantly increased the percent of CD138+ cells and the 
percent of CD45R/B220- cells (Fig. 3B and C).   
      
3.5. Attenuation by AA-2G of the decrease in viable cell number  
      
We noticed during the ELISPOT assay in the experiments for which results 
are shown in Figure 3A that the viable cell number in cultures treated with 
AA-2G was larger than that in cultures without AA-2G: an approximately 70% 
increase in the former (Fig. 3A). The increase in viable cell number may 
contribute to enhanced IgM production. The time course for changes in viable cell 
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number in cultures treated with and without AA-2G during the second culture was 
then determined. The number of viable cells in cultures without AA-2G 
progressively decreased with incubation time even in the presence of IL-4 and 
IL-5, but the decrease was significantly attenuated by AA-2G (Fig. 4A). In order 
to elucidate the mechanism responsible for the slower decrease in cell number, we 
next determined the proliferation and apoptosis of B cells incubated with or 
without AA-2G in the second culture. Cell proliferation was determined by 
[3H]thymidine uptake, expressed as the amount of [3H]thymidine incorporated per 
105 viable cells. DNA synthesis in cultures without AA-2G decreased more 
sharply during the second culture than the number of viable cells did (Fig. 4B and 
A). AA-2G caused a slight but reproducible inhibition of the decrease in DNA 
synthesis on day 2 of the second culture (Fig. 4B). Figure 4C and D shows the 
flow cytometric analysis of cells treated with or without AA-2G for 2 and 4 days. 
The DNA of cells fixed in ethanol was stained with PI. Apoptotic cells, those with 
a fractional DNA content, as indicated by bars, were decreased on day 4 of the 
second culture by treatment with AA-2G. 
 
4. Discussion 
 
Our results presented here demonstrated that AA-2G added in the reculture 
period promoted IL-4- and IL-5-dependent differentiation of anti-μ-primed B 
cells: AA-2G increased the number of IgM-secreting cells, CD138+ cells and 
CD45R/B220- cells, resulting in augmentation of IgM production. Those effects 
of AA-2G may be mediated by AA continuously released from AA-2G through 
the action of α-glucosidase because AA-2G-enhanced IgM production was 
suppressed to the level of IgM production in cells incubated without AA-2G by 
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the α-glucosidase inhibitor castanospermine. Indeed, intracellular levels of AA in 
B cells, which was depleted for 2 days during the priming period, were 
remarkably increased in the reculture period by addition of AA-2G. The level of 
intracellular AA-2G was undetectable (less than 17 ng/106 cells) at 2 and 4 days 
after addition (our unpublished data), suggesting that AA-2G is not efficiently 
transported into the cells. The time course for depletion of intracellular AA is 
similar to the time courses reported for murine T-cell-depleted splenocytes and 
human tonsilar B cells in culture [2,27]. Since α-glucosidase activity in the 
medium supplemented with 10% fetal bovine serum is very low for hydrolysis of 
AA-2G [22] , the conversion of AA-2G to AA may be catalyzed by cellular 
α-glucosidase of B lymphocytes. In contrast to AA-2G, single addition of AA in 
the reculture period of B cells did not increase IgM production due to instability 
of the vitamin in the culture medium [22]. Previous studies have shown that 
AA-2G as well as 2-O-octadecylascorbic acid, AA-2P and AA-2S have a 
scavenging activity for radicals such as 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
radical and 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical 
without being hydrolyzed to AA, although the reaction of the AA derivatives with 
radicals is much slower than that of AA with radicals [28-30]. However, since 
AA-2G-promoted IgM production was almost completely inhibited by 
castanospermine (Fig. 2A) and since AA-2S with a radical scavenging activity did 
not increase IgM production (Fig. 2C), it seems likely that the contribution of 
radical-scavenging activity of AA-2G itself to AA-2G-induced augmentation of 
IgM production is minimal, if any.  
Castanospermine is a potent competitive inhibitor of α- and β-glucosidases, 
but also inhibits the glycoprotein processing glucosidases glucosidase I and 
glucosidase II [31,32]. Castanospermine causes the change in oligosaccharide 
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structure of glycoproteins to the immature type by preventing glucose trimming 
from newly synthesized glycoproteins. Thus, cells treated with castanosperrmine 
occasionally have fewer receptors at the cell surface or show impaired signal 
transduction of receptors including IL-2 receptor [32,33]. However, IgM 
production by IL-4- and IL-5-stimulated B cells primed with anti-μ was not 
inhibited by castanospermine (Fig. 2A), and to our knowledge, impared 
expression, binding ability and signal transduction of IL-4 and IL-5 receptors 
have not been reported in cells incubated with castanospermine. Therefore, it is 
unlikely that inhibition of AA-2G-induced IgM production by castanospermine 
was caused by its inhibition of the glycoprotein processing glucosidases.  
The antioxidants Trolox, glutathione, and uric acid were ineffective in 
enhancing IgM production. These data suggest that the antioxidant activity is not 
the mechanism involved in AA-2G-induced production of IgM. However, the 
promoting effect of AA-2G was not observed before day 4 of secondary culture 
(Fig. 1C). We cannot rule out the possibility that activities of those antioxidants 
was not maintained during the whole culture period.  
The effect of AA-2G on differentiation of B cells was not further potentiated 
even when AA-2G was included in both the priming period and the reculture 
period. This implies that the initial AA levels present in B cells at the start of 
priming are high enough to elicit activity of AA if any or that AA has no 
important function in priming. Purified B cells contain millimolar concentrations 
of AA, which are much higher than those in plasma (50−150 μM), but the levels 
of intracellular AA decrease during cell culture [2]. The initial intracellular 
concentration of AA is maintained by exogenous AA added to cultures repeatedly 
at 12-hr intervals but not by single addition of AA because of its instability in the 
culture medium [2]. Single addition of AA-2G, however, is sufficient to restore 
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and maintain the initial intracellular levels of AA for several days as shown in this 
study and other studies [27,34]. Thus, AA-2G might be a useful tool for investing 
the physiological role of AA in long culture systems in vitro.  
When a value of reported cell volume of resting mouse B cells (100 μm3) is 
used [35], the AA concentration in the cells at 0 h in Fig. 2B is calculated to be 
2.7 mM that is not so different from the AA concentration (about 1.5 mM) in 
human B cells [2]. The intracellular concentration of AA is calculated to be 16 
mM at 4 and 6 days after addition of AA-2G that is much greater than the initial 
concentration. Thus, our results suggest that antidoby production by B cells is 
augmented by AA of concentrations higher than the normal concentration. AA-2G 
may be helpful in increasing concentrations of AA in B cells.  
AA-2G prevented the gradual decrease in the number of viable cells that 
occurred in anti-μ-stimulated B cell cultures even in the presence of IL-4 and IL-5. 
The resulting more viable cells in AA-2G-treated cultures (approximate 70% 
more cells) than in untreated cultures, however, can not fully explain the 
AA-2G-induced increase in number of IgM-secreting cells (160%). Thus, 
AA-2G-induced differentiation of B cells into plasma cells may contribute to the 
difference (90% increase) between the two values. The mechanism involved in 
AA-2G-induced B cell differentiation remains to be determined. In this 
connection, it is noteworthy that AA has increased nuclear binding of the 
transcription factor AP-1 [36,37]. AP-1 has been shown to positively regulate 
expression of B-lymphocyte-induced maturation protein 1, one of key 
transcription factors in B cell terminal differentiation, and differentiation of 
activated B cells [38,39]. We are presently attempting to determine whether 
B-lymphocyte-induced maturation protein 1 expression in B cells is regulated by 
AA-2G. As for AA-2G-induced attenuation of the decrease in viable cell number, 
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our results suggest that this effect is at least partly due to both the inhibition of 
apoptosis and enhancement of DNA synthesis. An anti-apoptotic effect of AA has 
been reported in several types of cells, including lymphocytes (40-42), but our 
results are the first report on ascorbate-induced protection of B cells from 
apoptosis.   
In conclusion, the results of this study demonstrated that AA released from 
AA-2G enhanced IgM production by B cells primed with anti-μ in the presence of 
IL-4 and IL-5 and suggested that its effect is caused through promoting the 
differentiation of B cells to plasma cells and attenuating the gradual decrease in 
the number of viable cells.  
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Figure legends 
 
Figure 1. Enhancement by AA-2G, but not by AA, of IL-4- and IL-5-dependent 
IgM production by B cells primed with anti-μ. B cells were primed with anti-μ for 
2 days in the presence (A−C) or absence (B) of IL-4 and IL-5 and then washed 
and recultured with the indicated doses of AA or AA-2G for 5 days (A,B) or with 
or without 0.5 mM AA-2G for the indicated days (C) in the presence (A−C) or 
absence (B) of IL-4 and IL-5. IgM in the culture supernatants was measured by an 
ELISA. The data are means ± S.D. or means and S.D. of three independent 
experiments. Values that are significantly different from those of the respective 
control cultures incubated without AA-2G or AA are indicated by *p < 0.05, ***p 
< 0.001 (Dunnett’s t-test) (A) and **p < 0.01 (Student’s t-test) (B,C).  
 
Figure 2. Enhancing effect of AA-2G mediated by released AA. B cells were 
primed with anti-μ for 2 days in the presence of IL-4 and IL-5 and then washed 
and recultured with or without AA-2G (0.5 mM), other stable AA derivatives (0.5 
mM) or the indicated concentrations of antioxidants for 5 days (A,C,D) or for 2 
and 4 days (B) in the presence of IL-4 and IL-5. (A) Inhibition of AA-2G-induced 
enhancement of IgM production in B cells by the α-glucosidase inhibitor 
castanospermine. (B) Changes in AA contents in the incubated B cells. AA 
contents in 1% metaphosphoric acid extracts of pooled cells were estimated by 
HPLC analysis. (C) Effects of other stable AA derivatives on IgM production in B 
cells. (D) Effects of antioxidants on IgM production in B cells. Trolox was 
dissolved in dimethyl sulfoxide (DMSO) and added to the medium at the final 
DMSO concentration of 0.05%. IgM in the culture supernatants was measured by 
an ELISA. The data are means and S.D. or means ± S.D. of three (A,B,D) or four 
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(C) independent experiments. (A) ***p < 0.001, as compared with the values of 
control cultures incubated without AA-2G and castanospermine (Bonferroni’s 
test). ##p < 0.01, ###p < 0.001, as compared with the values of cultures incubated 
with AA-2G alone (Bonferroni’s test). (B) **p < 0.01, as compared with the 
values of zero time cells (Dunnett’s T3-test). (C) *p < 0.05, as compared with the 
values of control cultures incubated without AA derivatives (Dunnett’s t-test). (D) 
**p < 0.01, ***p < 0.001, as compared with the values of control cultures 
incubated without antioxidants (Dunnett’s t-test). 
 
Figure 3. Increase by AA-2G in the number of IgM-secreting cells, CD138+ cells 
and CD45R/B220- cells elicited by anti-μ, IL-4 and IL-5. B cells were primed 
with anti-μ for 2 days in the presence of IL-4 and IL-5 and then washed and 
recultured with or without 0.5 mM AA-2G for 4.5 days (A) or 4 days (B,C) in the 
presence of IL-4 and IL-5. (A) The number of IgM-secreting cells and the number 
of viable cells were measured by an ELISPOT assay and the trypan blue 
dye-exclusion test, respectively. (B,C) The cells were stained with PE-conjugated 
anti-CD138 mAb and PI (B) or FITC-conjugated anti-CD45R/B220 mAb and PI 
(C) and analyzed by a flow cytometer. The data are means and S.D. of three 
independent experiments (A−C). Histograms (B,C) are representative of three 
independent experiments. *p < 0.05, ***p < 0.001, as compared with the values 
of control cultures incubated without AA-2G (Student’s t-test). 
 
Figure 4. Effects of AA-2G on viable cell number, DNA synthesis and apoptosis 
in B cells stimulated with anti-μ, IL-4 and IL-5. B cells were primed with anti-μ 
for 2 days in the presence of IL-4 and IL-5 and then washed and recultured with 
or without 0.5 mM AA-2G for the indicated days in the presence of IL-4 and IL-5. 
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(A) Attenuation by AA-2G of the gradual decrease in viable cell number during 
the reculture period. The number of viable cells was determined by the trypan 
blue dye-exclusion test. (B) Enhancement by AA-2G of DNA synthesis in B cells 
stimulated with anti-μ, IL-4 and IL-5. Cells were labeled with [3H]thymidine for 
the last 4 h. The number of viable cells in parallel cultures was determined by the 
trypan blue dye-exclusion test. (C,D) Inhibition of apoptosis by AA-2G in B cells 
stimulated with anti-μ, IL-4 and IL-5. Cells that had been fixed with 70% ethanol 
and incubated with ribonuclease A were stained with PI, and the DNA contents of 
cells were analyzed by a flow cytometer. The cells with a sub-G1 DNA content 
were regarded as apoptotic cells. The data are means ± S.D. or means and S.D. of 
three independent experiments. Histograms (C) are representative of three 
independent experiments. Values that are significantly different from the 
respective control cultures incubated without AA-2G are indicated by *p < 0.05, 
**p < 0.01 (Student’s t-test). 
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